BioBehavioral Diagnostics Lands $10,000,000 Series B Funding

  • Feed Type
  • Date
    2/1/2010
  • Company Name
    BioBehavioral Diagnostics
  • Mailing Address
    239 Littleton Road Westford, MA 01886
  • Company Description
    BioBehavioral Diagnostics Company (BioBDx) is a privately held company whose
    mission is to develop, manufacture, and market proprietary diagnostic systems for the
    quantitative assessment of behavioral disorders, including the measurement of medication
    response and the prediction of therapeutic efficacy for a patient. The company’s lead
    product, the McLean Motion and Attention Test for Attention Deficit Hyperactivity
    Disorder (MMAT/ADHD™ System), is designed to enable clinicians to accurately make
    office based diagnoses for ADHD, select the right class of medication, and measure
    therapeutic efficacy of a given drug while determining an optimal dosage. The BioBDx
    product portfolio includes ADHD diagnostic aid systems for children, adolescents, and
    adults. The MMAT/ADHD™ System is currently FDA approved as an aid for the
    diagnosis of ADHD.
  • Website
    http://www.biobdx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to expand sales and marketing activities as well as to execute additional clinical work for the Quotient ADHD System.
  • M&A Terms
  • Venture Investor
    Sevin Rosen Funds
  • Venture Investor
    Tullis Health Investors

By posting a comment, you agree to our terms and conditions.